11 Best Cancer Stocks to Buy Right Now

4. Incyte Corporation (NASDAQ:INCY)

Number of Hedge Fund Holders: 42 

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and inflammatory diseases, best known for Jakafi (ruxolitinib), a leading treatment for myelofibrosis and polycythemia vera. Its oncology portfolio also includes MONJUVI for lymphoma, PEMAZYRE for cholangiocarcinoma, ZYNYZ for Merkel cell carcinoma, and NIKTIMVO for chronic graft-versus-host disease, along with Opzelura for inflammatory skin conditions.

In Q2 2025, Jakafi delivered $764 million in revenue, an 8% year-over-year increase, prompting the company to raise full-year sales guidance to $3.0–3.05 billion. Strong demand and supportive healthcare policies have reinforced Jakafi’s growth, driving Incyte Corporation (NASDAQ:INCY)’s overall financial performance.

The business is expanding its precision medicine efforts through a global partnership with QIAGEN, developing a companion diagnostic for mutant calreticulin (mutCALR) to better identify patients for its investigational therapy INCA033989 in rare blood cancers.

Incyte Corporation (NASDAQ:INCY) reported positive Phase 2 results for povorcitinib, an oral JAK1 inhibitor for chronic spontaneous urticaria, underscoring diversification into immunology and dermatology. The corporation is also advancing a KRAS G12D inhibitor for pancreatic cancer, with potential as both a standalone and combination therapy.

Looking ahead, the firm expects 18+ clinical milestones in 2025, including four potential product launches, highlighting aggressive R&D investment across oncology and immune-related conditions.